NCT07091019 2025-07-29
ASC4REAL-2
Novartis
Not yet recruiting
Clinical Trials
10 trialsNCT05286528 2023-10-27
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Pfizer
Completed
NCT03885830 2023-01-11
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
UNC Lineberger Comprehensive Cancer Center
Completed
NCT03318770 2022-10-12
Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT02421926 2019-07-08
IDEAL-E
Asan Medical Center
Withdrawn
NCT03331211 2017-11-08
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
Unknown
NCT02389972 2017-09-11
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
Bristol-Myers Squibb
Completed
NCT02546791 2017-07-26
PASS
Bristol-Myers Squibb
Completed
NCT01188278 2016-09-30
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
Bristol-Myers Squibb
Completed
NCT02733445 2016-04-11
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
Bristol-Myers Squibb
Completed